Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 1505 entries
Sorted by: Best Match Show Resources per page
Unusual case of drug-induced cholestasis due to glucosamine and chondroitin sulfate.

World journal of hepatology

Ip S, Jeong R, Schaeffer DF, Yoshida EM.
PMID: 26527309
World J Hepatol. 2015 Oct 28;7(24):2559-62. doi: 10.4254/wjh.v7.i24.2559.

Glucosamine (GS) and chondroitin sulfate (CS) are common over-the-counter (OTC) supplements used in the treatment of osteoarthritis. These medications are seemingly safe, but there are increasing reports of hepatotoxicity with these supplements. We reported a unique case of drug-induced...

Cite
Ip S, Jeong R, Schaeffer DF, et al. Unusual case of drug-induced cholestasis due to glucosamine and chondroitin sulfate. World J Hepatol. 2015;7(24):2559-62doi: 10.4254/wjh.v7.i24.2559.
Ip, S., Jeong, R., Schaeffer, D. F., & Yoshida, E. M. (2015). Unusual case of drug-induced cholestasis due to glucosamine and chondroitin sulfate. World journal of hepatology, 7(24), 2559-62. https://doi.org/10.4254/wjh.v7.i24.2559
Ip, Stephen, et al. "Unusual case of drug-induced cholestasis due to glucosamine and chondroitin sulfate." World journal of hepatology vol. 7,24 (2015): 2559-62. doi: https://doi.org/10.4254/wjh.v7.i24.2559
Ip S, Jeong R, Schaeffer DF, Yoshida EM. Unusual case of drug-induced cholestasis due to glucosamine and chondroitin sulfate. World J Hepatol. 2015 Oct 28;7(24):2559-62. doi: 10.4254/wjh.v7.i24.2559. PMID: 26527309; PMCID: PMC4621470.
Copy Download .nbib Format: NLM
Risk factors for hepatocellular carcinoma in cirrhosis due to nonalcoholic fatty liver disease: A multicenter, case-control study.

World journal of hepatology

Corey KE, Gawrieh S, deLemos AS, Zheng H, Scanga AE, Haglund JW, Sanchez J, Danford CJ, Comerford M, Bossi K, Munir S, Chalasani N, Wattacheril J.
PMID: 28321274
World J Hepatol. 2017 Mar 08;9(7):385-390. doi: 10.4254/wjh.v9.i7.385.

AIM: To identify risk factors associated with hepatocellular carcinoma (HCC), describe tumor characteristics and treatments pursed for a cohort of individuals with nonalcoholic steatohepatitis (NASH) cirrhosis.METHODS: We conducted a retrospective case-control study of a well-characterized cohort of patients among...

Cite
Corey KE, Gawrieh S, deLemos AS, et al. Risk factors for hepatocellular carcinoma in cirrhosis due to nonalcoholic fatty liver disease: A multicenter, case-control study. World J Hepatol. 2017;9(7):385-390doi: 10.4254/wjh.v9.i7.385.
Corey, K. E., Gawrieh, S., deLemos, A. S., Zheng, H., Scanga, A. E., Haglund, J. W., Sanchez, J., Danford, C. J., Comerford, M., Bossi, K., Munir, S., Chalasani, N., & Wattacheril, J. (2017). Risk factors for hepatocellular carcinoma in cirrhosis due to nonalcoholic fatty liver disease: A multicenter, case-control study. World journal of hepatology, 9(7), 385-390. https://doi.org/10.4254/wjh.v9.i7.385
Corey, Kathleen E, et al. "Risk factors for hepatocellular carcinoma in cirrhosis due to nonalcoholic fatty liver disease: A multicenter, case-control study." World journal of hepatology vol. 9,7 (2017): 385-390. doi: https://doi.org/10.4254/wjh.v9.i7.385
Corey KE, Gawrieh S, deLemos AS, Zheng H, Scanga AE, Haglund JW, Sanchez J, Danford CJ, Comerford M, Bossi K, Munir S, Chalasani N, Wattacheril J. Risk factors for hepatocellular carcinoma in cirrhosis due to nonalcoholic fatty liver disease: A multicenter, case-control study. World J Hepatol. 2017 Mar 08;9(7):385-390. doi: 10.4254/wjh.v9.i7.385. PMID: 28321274; PMCID: PMC5340993.
Copy Download .nbib Format: NLM
Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease.

World journal of hepatology

Puchakayala BK, Verma S, Kanwar P, Hart J, Sanivarapu RR, Mohanty SR.
PMID: 26557954
World J Hepatol. 2015 Nov 08;7(25):2610-8. doi: 10.4254/wjh.v7.i25.2610.

AIM: To study clinical and histopathological features of nonalcoholic fatty liver disease (NAFLD) in patients with and without type 2 diabetes mellitus (T2DM) using updated nonalcoholic steatohepatitis clinical research network (NASH-CRN) grading system.METHODS: We retrospectively analyzed data of 235...

Cite
Puchakayala BK, Verma S, Kanwar P, et al. Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease. World J Hepatol. 2015;7(25):2610-8doi: 10.4254/wjh.v7.i25.2610.
Puchakayala, B. K., Verma, S., Kanwar, P., Hart, J., Sanivarapu, R. R., & Mohanty, S. R. (2015). Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease. World journal of hepatology, 7(25), 2610-8. https://doi.org/10.4254/wjh.v7.i25.2610
Puchakayala, Bharat K, et al. "Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease." World journal of hepatology vol. 7,25 (2015): 2610-8. doi: https://doi.org/10.4254/wjh.v7.i25.2610
Puchakayala BK, Verma S, Kanwar P, Hart J, Sanivarapu RR, Mohanty SR. Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease. World J Hepatol. 2015 Nov 08;7(25):2610-8. doi: 10.4254/wjh.v7.i25.2610. PMID: 26557954; PMCID: PMC4635147.
Copy Download .nbib Format: NLM
Human immunodeficiency virus and viral hepatitis among high-risk groups: Understanding the knowledge gap in the Middle East and North Africa Region.

World journal of hepatology

Melhem NM, Rahhal N, Charide R, Kreidieh K, El-Khatib R.
PMID: 26557955
World J Hepatol. 2015 Nov 08;7(25):2619-30. doi: 10.4254/wjh.v7.i25.2619.

AIM: To identify gaps in the existing knowledge on single, dual and triple infections of human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) in the Middle East and North Africa (MENA) region among men...

Cite
Melhem NM, Rahhal N, Charide R, et al. Human immunodeficiency virus and viral hepatitis among high-risk groups: Understanding the knowledge gap in the Middle East and North Africa Region. World J Hepatol. 2015;7(25):2619-30doi: 10.4254/wjh.v7.i25.2619.
Melhem, N. M., Rahhal, N., Charide, R., Kreidieh, K., & El-Khatib, R. (2015). Human immunodeficiency virus and viral hepatitis among high-risk groups: Understanding the knowledge gap in the Middle East and North Africa Region. World journal of hepatology, 7(25), 2619-30. https://doi.org/10.4254/wjh.v7.i25.2619
Melhem, Nada M, et al. "Human immunodeficiency virus and viral hepatitis among high-risk groups: Understanding the knowledge gap in the Middle East and North Africa Region." World journal of hepatology vol. 7,25 (2015): 2619-30. doi: https://doi.org/10.4254/wjh.v7.i25.2619
Melhem NM, Rahhal N, Charide R, Kreidieh K, El-Khatib R. Human immunodeficiency virus and viral hepatitis among high-risk groups: Understanding the knowledge gap in the Middle East and North Africa Region. World J Hepatol. 2015 Nov 08;7(25):2619-30. doi: 10.4254/wjh.v7.i25.2619. PMID: 26557955; PMCID: PMC4635148.
Copy Download .nbib Format: NLM
Serum 25-hydroxyvitamin D deficiency and hepatic encephalopathy in chronic liver disease.

World journal of hepatology

Vidot H, Potter A, Cheng R, Allman-Farinelli M, Shackel N.
PMID: 28443156
World J Hepatol. 2017 Apr 08;9(10):510-518. doi: 10.4254/wjh.v9.i10.510.

AIM: To investigate the relationship between 25-hydroxyvitamin D (25-OHD) deficiency and hepatic encephalopathy (HE) in patients with chronic liver disease (CLD).METHODS: A retrospective analysis of the results of 392 adult patients with chronic liver disease who were assessed for...

Cite
Vidot H, Potter A, Cheng R, et al. Serum 25-hydroxyvitamin D deficiency and hepatic encephalopathy in chronic liver disease. World J Hepatol. 2017;9(10):510-518doi: 10.4254/wjh.v9.i10.510.
Vidot, H., Potter, A., Cheng, R., Allman-Farinelli, M., & Shackel, N. (2017). Serum 25-hydroxyvitamin D deficiency and hepatic encephalopathy in chronic liver disease. World journal of hepatology, 9(10), 510-518. https://doi.org/10.4254/wjh.v9.i10.510
Vidot, Helen, et al. "Serum 25-hydroxyvitamin D deficiency and hepatic encephalopathy in chronic liver disease." World journal of hepatology vol. 9,10 (2017): 510-518. doi: https://doi.org/10.4254/wjh.v9.i10.510
Vidot H, Potter A, Cheng R, Allman-Farinelli M, Shackel N. Serum 25-hydroxyvitamin D deficiency and hepatic encephalopathy in chronic liver disease. World J Hepatol. 2017 Apr 08;9(10):510-518. doi: 10.4254/wjh.v9.i10.510. PMID: 28443156; PMCID: PMC5387363.
Copy Download .nbib Format: NLM
Intestinal barrier dysfunction in cirrhosis: Current concepts in pathophysiology and clinical implications.

World journal of hepatology

Tsiaoussis GI, Assimakopoulos SF, Tsamandas AC, Triantos CK, Thomopoulos KC.
PMID: 26301048
World J Hepatol. 2015 Aug 18;7(17):2058-68. doi: 10.4254/wjh.v7.i17.2058.

The intestinal lumen is a host place for a wide range of microbiota and sets a unique interplay between local immune system, inflammatory cells and intestinal epithelium, forming a physical barrier against microbial invaders and toxins. Bacterial translocation is...

Cite
Tsiaoussis GI, Assimakopoulos SF, Tsamandas AC, et al. Intestinal barrier dysfunction in cirrhosis: Current concepts in pathophysiology and clinical implications. World J Hepatol. 2015;7(17):2058-68doi: 10.4254/wjh.v7.i17.2058.
Tsiaoussis, G. I., Assimakopoulos, S. F., Tsamandas, A. C., Triantos, C. K., & Thomopoulos, K. C. (2015). Intestinal barrier dysfunction in cirrhosis: Current concepts in pathophysiology and clinical implications. World journal of hepatology, 7(17), 2058-68. https://doi.org/10.4254/wjh.v7.i17.2058
Tsiaoussis, Georgios I, et al. "Intestinal barrier dysfunction in cirrhosis: Current concepts in pathophysiology and clinical implications." World journal of hepatology vol. 7,17 (2015): 2058-68. doi: https://doi.org/10.4254/wjh.v7.i17.2058
Tsiaoussis GI, Assimakopoulos SF, Tsamandas AC, Triantos CK, Thomopoulos KC. Intestinal barrier dysfunction in cirrhosis: Current concepts in pathophysiology and clinical implications. World J Hepatol. 2015 Aug 18;7(17):2058-68. doi: 10.4254/wjh.v7.i17.2058. PMID: 26301048; PMCID: PMC4539399.
Copy Download .nbib Format: NLM
New treatment strategies for hepatitis C infection.

World journal of hepatology

Ermis F, Senocak Tasci E.
PMID: 26301052
World J Hepatol. 2015 Aug 18;7(17):2100-9. doi: 10.4254/wjh.v7.i17.2100.

Hepatitis C infection can lead to cirrhosis and hepatocellular carcinoma and it is an important cause of mortality and morbidity. Achieving a sustained virological response has been the major aim for decades. Interferon treatment was the primarily developed therapy...

Cite
Ermis F, Senocak Tasci E. New treatment strategies for hepatitis C infection. World J Hepatol. 2015;7(17):2100-9doi: 10.4254/wjh.v7.i17.2100.
Ermis, F., & Senocak Tasci, E. (2015). New treatment strategies for hepatitis C infection. World journal of hepatology, 7(17), 2100-9. https://doi.org/10.4254/wjh.v7.i17.2100
Ermis, Fatih, and Senocak Tasci, Elif. "New treatment strategies for hepatitis C infection." World journal of hepatology vol. 7,17 (2015): 2100-9. doi: https://doi.org/10.4254/wjh.v7.i17.2100
Ermis F, Senocak Tasci E. New treatment strategies for hepatitis C infection. World J Hepatol. 2015 Aug 18;7(17):2100-9. doi: 10.4254/wjh.v7.i17.2100. PMID: 26301052; PMCID: PMC4539403.
Copy Download .nbib Format: NLM
Predictive potential of IL-28B genetic testing for interferon based hepatitis C virus therapy in Pakistan: Current scenario and future perspective.

World journal of hepatology

Afzal MS.
PMID: 27660680
World J Hepatol. 2016 Sep 18;8(26):1116-8. doi: 10.4254/wjh.v8.i26.1116.

In Pakistan which ranked second in terms of hepatitis C virus (HCV) infection, it is highly needed to have an established diagnostic test for antiviral therapy response prediction. Interleukin 28B (IL-28B) genetic testing is widely used throughout the world...

Cite
Afzal MS. Predictive potential of IL-28B genetic testing for interferon based hepatitis C virus therapy in Pakistan: Current scenario and future perspective. World J Hepatol. 2016;8(26):1116-8doi: 10.4254/wjh.v8.i26.1116.
Afzal, M. S. (2016). Predictive potential of IL-28B genetic testing for interferon based hepatitis C virus therapy in Pakistan: Current scenario and future perspective. World journal of hepatology, 8(26), 1116-8. https://doi.org/10.4254/wjh.v8.i26.1116
Afzal, Muhammad Sohail. "Predictive potential of IL-28B genetic testing for interferon based hepatitis C virus therapy in Pakistan: Current scenario and future perspective." World journal of hepatology vol. 8,26 (2016): 1116-8. doi: https://doi.org/10.4254/wjh.v8.i26.1116
Afzal MS. Predictive potential of IL-28B genetic testing for interferon based hepatitis C virus therapy in Pakistan: Current scenario and future perspective. World J Hepatol. 2016 Sep 18;8(26):1116-8. doi: 10.4254/wjh.v8.i26.1116. PMID: 27660680; PMCID: PMC5026995.
Copy Download .nbib Format: NLM
Role of interleukin-1 and its antagonism of hepatic stellate cell proliferation and liver fibrosis in the Abcb4(-/-) mouse model.

World journal of hepatology

Reiter FP, Wimmer R, Wottke L, Artmann R, Nagel JM, Carranza MO, Mayr D, Rust C, Fickert P, Trauner M, Gerbes AL, Hohenester S, Denk GU.
PMID: 27004088
World J Hepatol. 2016 Mar 18;8(8):401-10. doi: 10.4254/wjh.v8.i8.401.

AIM: To study the interleukin-1 (IL-1) pathway as a therapeutic target for liver fibrosis in vitro and in vivo using the ATP-binding cassette transporter b4(-/-) (Abcb4(-/-)) mouse model.METHODS: Female and male Abcb4(-/-) mice from 6 to 13 mo of...

Cite
Reiter FP, Wimmer R, Wottke L, et al. Role of interleukin-1 and its antagonism of hepatic stellate cell proliferation and liver fibrosis in the Abcb4(-/-) mouse model. World J Hepatol. 2016;8(8):401-10doi: 10.4254/wjh.v8.i8.401.
Reiter, F. P., Wimmer, R., Wottke, L., Artmann, R., Nagel, J. M., Carranza, M. O., Mayr, D., Rust, C., Fickert, P., Trauner, M., Gerbes, A. L., Hohenester, S., & Denk, G. U. (2016). Role of interleukin-1 and its antagonism of hepatic stellate cell proliferation and liver fibrosis in the Abcb4(-/-) mouse model. World journal of hepatology, 8(8), 401-10. https://doi.org/10.4254/wjh.v8.i8.401
Reiter, Florian P, et al. "Role of interleukin-1 and its antagonism of hepatic stellate cell proliferation and liver fibrosis in the Abcb4(-/-) mouse model." World journal of hepatology vol. 8,8 (2016): 401-10. doi: https://doi.org/10.4254/wjh.v8.i8.401
Reiter FP, Wimmer R, Wottke L, Artmann R, Nagel JM, Carranza MO, Mayr D, Rust C, Fickert P, Trauner M, Gerbes AL, Hohenester S, Denk GU. Role of interleukin-1 and its antagonism of hepatic stellate cell proliferation and liver fibrosis in the Abcb4(-/-) mouse model. World J Hepatol. 2016 Mar 18;8(8):401-10. doi: 10.4254/wjh.v8.i8.401. PMID: 27004088; PMCID: PMC4794530.
Copy Download .nbib Format: NLM
Passive expansion of sub-maximally dilated transjugular intrahepatic portosystemic shunts and assessment of clinical outcomes.

World journal of hepatology

Hsu MC, Weber CN, Stavropoulos SW, Clark TW, Trerotola SO, Shlansky-Goldberg RD, Soulen MC, Nadolski GJ.
PMID: 28515846
World J Hepatol. 2017 Apr 28;9(12):603-612. doi: 10.4254/wjh.v9.i12.603.

AIM: To assess for passive expansion of sub-maximally dilated transjugular intrahepatic portosystemic shunts (TIPS) and compare outcomes with maximally dilated TIPS.METHODS: Polytetrafluoroethylene covered TIPS (Viatorr) from July 2002 to December 2013 were retrospectively reviewed at two hospitals in a...

Cite
Hsu MC, Weber CN, Stavropoulos SW, et al. Passive expansion of sub-maximally dilated transjugular intrahepatic portosystemic shunts and assessment of clinical outcomes. World J Hepatol. 2017;9(12):603-612doi: 10.4254/wjh.v9.i12.603.
Hsu, M. C., Weber, C. N., Stavropoulos, S. W., Clark, T. W., Trerotola, S. O., Shlansky-Goldberg, R. D., Soulen, M. C., & Nadolski, G. J. (2017). Passive expansion of sub-maximally dilated transjugular intrahepatic portosystemic shunts and assessment of clinical outcomes. World journal of hepatology, 9(12), 603-612. https://doi.org/10.4254/wjh.v9.i12.603
Hsu, Michael C, et al. "Passive expansion of sub-maximally dilated transjugular intrahepatic portosystemic shunts and assessment of clinical outcomes." World journal of hepatology vol. 9,12 (2017): 603-612. doi: https://doi.org/10.4254/wjh.v9.i12.603
Hsu MC, Weber CN, Stavropoulos SW, Clark TW, Trerotola SO, Shlansky-Goldberg RD, Soulen MC, Nadolski GJ. Passive expansion of sub-maximally dilated transjugular intrahepatic portosystemic shunts and assessment of clinical outcomes. World J Hepatol. 2017 Apr 28;9(12):603-612. doi: 10.4254/wjh.v9.i12.603. PMID: 28515846; PMCID: PMC5411955.
Copy Download .nbib Format: NLM
Hepatitis B in patients with hematological diseases: An update.

World journal of hepatology

Coluccio C, Begini P, Marzano A, Pellicelli A, Imperatrice B, Anania G, Delle Fave G, Marignani M.
PMID: 28951776
World J Hepatol. 2017 Sep 08;9(25):1043-1053. doi: 10.4254/wjh.v9.i25.1043.

Hepatitis B virus (HBV) reactivation (HBVr) in patients undergoing immunosuppressive therapy is still a hot topic worldwide. Its prevention and management still represents a challenge for specialists dealing with immunosuppressed patients. Aim of this paper is to provide a...

Cite
Coluccio C, Begini P, Marzano A, et al. Hepatitis B in patients with hematological diseases: An update. World J Hepatol. 2017;9(25):1043-1053doi: 10.4254/wjh.v9.i25.1043.
Coluccio, C., Begini, P., Marzano, A., Pellicelli, A., Imperatrice, B., Anania, G., Delle Fave, G., & Marignani, M. (2017). Hepatitis B in patients with hematological diseases: An update. World journal of hepatology, 9(25), 1043-1053. https://doi.org/10.4254/wjh.v9.i25.1043
Coluccio, Chiara, et al. "Hepatitis B in patients with hematological diseases: An update." World journal of hepatology vol. 9,25 (2017): 1043-1053. doi: https://doi.org/10.4254/wjh.v9.i25.1043
Coluccio C, Begini P, Marzano A, Pellicelli A, Imperatrice B, Anania G, Delle Fave G, Marignani M. Hepatitis B in patients with hematological diseases: An update. World J Hepatol. 2017 Sep 08;9(25):1043-1053. doi: 10.4254/wjh.v9.i25.1043. PMID: 28951776; PMCID: PMC5596311.
Copy Download .nbib Format: NLM
Characteristics of escape mutations from occult hepatitis B virus infected patients with hematological malignancies in South Egypt.

World journal of hepatology

Elkady A, Iijima S, Aboulfotuh S, Mostafa Ali E, Sayed D, Abdel-Aziz NM, Ali AM, Murakami S, Isogawa M, Tanaka Y.
PMID: 28396718
World J Hepatol. 2017 Mar 28;9(9):477-486. doi: 10.4254/wjh.v9.i9.477.

AIM: To investigate the prevalence and virological characteristics of occult hepatitis B virus (HBV) infections in patients with hematological malignancies in South Egypt.METHODS: Serum samples were collected from 165 patients with hematological malignancies to monitor titers of HBV DNA,...

Cite
Elkady A, Iijima S, Aboulfotuh S, et al. Characteristics of escape mutations from occult hepatitis B virus infected patients with hematological malignancies in South Egypt. World J Hepatol. 2017;9(9):477-486doi: 10.4254/wjh.v9.i9.477.
Elkady, A., Iijima, S., Aboulfotuh, S., Mostafa Ali, E., Sayed, D., Abdel-Aziz, N. M., Ali, A. M., Murakami, S., Isogawa, M., & Tanaka, Y. (2017). Characteristics of escape mutations from occult hepatitis B virus infected patients with hematological malignancies in South Egypt. World journal of hepatology, 9(9), 477-486. https://doi.org/10.4254/wjh.v9.i9.477
Elkady, Abeer, et al. "Characteristics of escape mutations from occult hepatitis B virus infected patients with hematological malignancies in South Egypt." World journal of hepatology vol. 9,9 (2017): 477-486. doi: https://doi.org/10.4254/wjh.v9.i9.477
Elkady A, Iijima S, Aboulfotuh S, Mostafa Ali E, Sayed D, Abdel-Aziz NM, Ali AM, Murakami S, Isogawa M, Tanaka Y. Characteristics of escape mutations from occult hepatitis B virus infected patients with hematological malignancies in South Egypt. World J Hepatol. 2017 Mar 28;9(9):477-486. doi: 10.4254/wjh.v9.i9.477. PMID: 28396718; PMCID: PMC5368625.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 1505 entries